Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 4 study of VPRIV for bone disease in treatment-naive type 1 Gaucher disease
MOH_2017-05-04_000363Phase 4Recruiting
- Sponsor
- Takeda
- Start
- Aug 2016
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of velaglucerase alfa in Gaucher disease type 1 (GD1), sponsored by Takeda. Primary endpoint: Change from baseline in lumbar spine bone mineral density Z-score at 24 months. Started Aug 2016; status: recruiting.
02
Drugs
velaglucerase alfa
03
Conditions
Gaucher disease type 1 (GD1)
Beyond the preview
Go deeper on MOH_2017-05-04_000363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-05-04_000363.